【Strength】20mcg/dose×200doses 【Brand】JEWIM or OEM 【Indication】It is indicated for the regular treatment of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD) and chronic asthma. 【Quality Standard】Current BP standard 【GMP Approval】Australia TGA GMP 【Packing】1piece/box, 300 boxes/carton 【MOQ】5000 pieces
【Composition】The active ingredient: Ipratropium Bromide
【Storage】Store below 30°C. Protect from frost and direct sunlight.
【Package】An inhaler comprising an aluminium canister sealed with a metering valve, actuator and dust cap, 1 canister per box.
【Shelf life】36 months
Qualitative and quantitative composition Each canister provides 200 actuations. After priming, each actuation of the inhaler delivers 21 mcg of ipratropium bromide monohydrate from the valve and delivers 17 mcg of ipratropium bromide monohydrate from the actuator
Therapeutic indications Ipratropium Pressurised Inhalation is indicated for the regular treatment of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD) and chronic asthma.
Posology and method of administration For inhalation use.
Adults (including the elderly): Usually 1 or 2 puffs three or four times daily, although some patients may need up to 4 puffs at a time to obtain maximum benefit during early treatment.
Children: 6-12 years: Usually 1 or 2 puffs three times daily. Under 6 years: Usually 1 puff three times daily. In order to ensure that the inhaler is used correctly, administration should be supervised by an adult.
The recommended dose should not be exceeded. If therapy does not produce a significant improvement, if the patient's condition gets worse or if a reduced response to treatment becomes apparent, medical advice must be sought. In the case of acute or rapidly worsening dyspnoea (difficulty in breathing) a doctor should be consulted immediately.
For detailed information please refer to product leaflet.
SPC for Ipratropium Pressurised Inhalation.pdf